MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
Novavax ROCE Ratio 2011-2026 | NVAX
Annual ROCE Ratio Novavax
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -354.43 | 39.9 | 79.02 | 101.68 | 479.59 | -66.44 | -88.06 | -107.07 | -75.04 | -82.07 | -50.8 | -34.6 | -24.16 | -32.72 | -36.58 | -65.19 | -53.44 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 479.59 | -354.43 | -21.79 |
Quarterly ROCE Ratio Novavax
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -288.6 | -273.8 | -424.72 | -676.64 | 4.87 | 23.39 | -9.42 | 62.8 | 46.09 | 68.57 | 165.88 | 493.62 | 458.69 | 392.12 | 323.26 | 187.35 | -133.04 | -163.96 | -100.1 | -57.36 | -37.29 | -29.23 | 21.4 | 45.74 | 49.39 | 74.34 | 91.29 | 97.49 | 75.87 | 116.79 | 132.6 | 147.73 | 121.82 | 1263.32 | 2601.74 | 3918.02 | 3877.89 | 3866.55 | 2717.93 | 1330.29 | -26.77 | -35.38 | -31.81 | -30.96 | -22.66 | -30.18 | -27.9 | -25.05 | -18.79 | -27.32 | -27.1 | -30.06 | -25.14 | -32.51 | -34.97 | -41.47 | -32.16 | -7.37 | -11.0 | -13.8 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3918.02 | -676.64 | 334.17 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-299.89 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-27.78 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
16.47 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-41.41 | - | 0.74 % | $ 768 M |  Israel |
 |
Galera Therapeutics
GRTX
|
-63.97 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-71.74 | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
-19.96 | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-3.23 | $ 33.32 | -4.81 % | $ 897 M | USA |
|
Forte Biosciences
FBRX
|
-115.85 | $ 22.02 | 0.09 % | $ 285 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-439.8 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-69.03 | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
-165.18 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-79.29 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
-7.08 | $ 92.8 | 2.06 % | $ 22.4 B | Germany |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.73 | 4.85 % | $ 460 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
6.19 | $ 7.98 | -1.61 % | $ 5.42 B |  Spain |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-123.17 | - | -4.36 % | $ 27 M | USA |
 |
Heron Therapeutics
HRTX
|
-17.71 | $ 0.87 | 0.41 % | $ 145 M | USA |
 |
Compugen Ltd.
CGEN
|
23.38 | $ 2.79 | 6.9 % | $ 261 M | Israel |
 |
Anika Therapeutics
ANIK
|
-7.7 | $ 14.78 | -1.63 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-76.42 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Incyte Corporation
INCY
|
29.32 | $ 96.93 | -0.5 % | $ 18.9 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.38 | -1.73 % | $ 5.56 M | Israel |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
-296.87 | $ 1.64 | 4.46 % | $ 192 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-155.07 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 20.79 | -1.05 % | $ 2.65 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |